Patents by Inventor Manmohan Reddy Leleti

Manmohan Reddy Leleti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20250145606
    Abstract: The present disclosure is directed to compounds having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
    Type: Application
    Filed: November 1, 2024
    Publication date: May 8, 2025
    Applicant: Arcus Biosciences, Inc.
    Inventors: Srijita Bhowmik, Karen Yir Jing Chen, Jeremy Fournier, Jenna Leigh Jeffrey, Manjunath Lamani, Manmohan Reddy Leleti, Guillaume Mata, Hyunyoung Moon, Pradeep Nareddy, Srinivas Paladugu, Zhang Wang, Xuelei Yan, Monika Yadav, Jiang Zhu
  • Inhibitors of ARG1 and/or ARG2
    Patent number: 12226425
    Abstract: Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: February 18, 2025
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Beatty, Eric Thomas Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Corinne Nicole Foley, Rebecca Louise Grange, Tezcan Guney, Steven Donald Jacob, Jaroslaw Kalisiak, Manmohan Reddy Leleti, Erick Allen Lindsey, Debashis Mandal
  • Compounds as inhibitors of AXL
    Patent number: 12195482
    Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.
    Type: Grant
    Filed: August 14, 2024
    Date of Patent: January 14, 2025
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Corinne Nicole Foley, Balint Gal, Manjunath Lamani, Manmohan Reddy Leleti, Dillon Harding Miles, Srinivas Paladugu, Jay Patrick Powers, Shiwei Qu
  • Azolopyrimidine for the treatment of cancer-related disorders
    Patent number: 12195447
    Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: January 14, 2025
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Joel Beatty, Laurent Debien, Jenna Jeffrey, Manmohan Reddy Leleti, Debashis Mandal, Dillon Miles, Jay Powers, Brandon Rosen, Ehesan Sharif, Rhiannon Thomas-Tran
  • CBL-B INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250011318
    Abstract: Disclosed herein are compounds having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
    Type: Application
    Filed: May 24, 2024
    Publication date: January 9, 2025
    Applicant: ARCUS BIOSCIENCES, INC.
    Inventors: Srikanth Kumar Gangam, Clayton Hardman, Kenneth Victor Lawson, Manmohan Reddy Leleti, Dongdong Liu, Artur Karenovich Mailyan, Masa Podunavac, Shiwei Qu, Zhang Wang, Xianglin Yin, Kai Yu, Tzu-Yu Yu
  • Cbl-b Inhibitors and Methods of Use Thereof
    Publication number: 20240425497
    Abstract: Disclosed herein are compounds that are Cbl-b inhibitors having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
    Type: Application
    Filed: May 3, 2024
    Publication date: December 26, 2024
    Applicant: ARCUS BIOSCIENCES, INC.
    Inventors: Srikanth Kumar Gangam, Clayton Hardman, Kenneth Victor Lawson, Manmohan Reddy Leleti, Dongdong Liu, Artur Karenovich Mailyan, Masa Podunavac, Shiwei Qu, Xianglin Yin, Kai Yu, Tzu-Yu Yu
  • COMPOUNDS AS INHIBITORS OF AXL
    Publication number: 20240425526
    Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.
    Type: Application
    Filed: August 14, 2024
    Publication date: December 26, 2024
    Applicant: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Corinne Nicole Foley, Balint Gal, Manjunath Lamani, Manmohan Reddy Leleti, Dillon Harding Miles, Srinivas Paladugu, Jay Patrick Powers, Shiwei Qu
  • Inhibitors of adenosine 5?-nucleotidase
    Patent number: 12168023
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: April 8, 2024
    Date of Patent: December 17, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Laurent Pierre Paul Debien, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Process for preparing tetralin compounds
    Patent number: 12145901
    Abstract: The present disclosure describes processes and intermediates useful for preparing a compound of Formula (Xa) or Formula (Xb). The processes and intermediates can be used to prepare the compounds of the disclosure at multigram or kilogram scale.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: November 19, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Fournier, Balint Gal, Karl T. Haelsig, Clayton Hardman, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Artur Karenovich Mailyan, Guillaume Mata, Brandon Reid Rosen, Zhang Wang, Kai Yu
  • 2-oxindole compounds
    Patent number: 12139475
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: November 12, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Manmohan Reddy Leleti, Rebecca M. Lui, Viengkham Malathong, Jay P. Powers, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF
    Publication number: 20240352057
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: November 21, 2023
    Publication date: October 24, 2024
    Inventors: Laurent Pierre Paul DEBIEN, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ui Sharif
  • Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
    Patent number: 12103907
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Grant
    Filed: August 30, 2023
    Date of Patent: October 1, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
  • CAPSULE FORMULATIONS
    Publication number: 20240299306
    Abstract: The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.
    Type: Application
    Filed: February 9, 2024
    Publication date: September 12, 2024
    Inventors: Manmohan Reddy LELETI, Jay P. POWERS
  • INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE
    Publication number: 20240285665
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: April 8, 2024
    Publication date: August 29, 2024
    Inventors: Laurent Pierre Paul DEBIEN, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan UI Sharif
  • Inhibitors of HIF-2? and methods of use thereof
    Patent number: 12071411
    Abstract: The present disclosure is directed to compounds that are inhibitors of HIF-2? having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: August 27, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Fournier, Balint Gal, Clayton Hardman, Artur Karenovich Mailyan, Kenneth Victor Lawson, Manmohan Reddy Leleti, Dongdong Liu, Guillaume Mata, Ma{hacek over (s)}a Podunavac, Jay Patrick Powers, Brandon Reid Rosen, Kai Yu
  • Pyridone A2R antagonists
    Patent number: 12064433
    Abstract: Compound that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: August 20, 2024
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Manmohan Reddy Leleti, Debashis Mandal, Dillon Harding Miles, Jay Patrick Powers, Brandon Reid Rosen, Ehesan U I Sharif
  • TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA
    Publication number: 20240254079
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Application
    Filed: August 30, 2023
    Publication date: August 1, 2024
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy Thomas Andre FOURNIER, Balint GAL, Tezcan GUNEY, Karl T. HAELSIG, Clayton HARDMAN, Steven Donald JACOB, Jenna Leigh JEFFREY, Jaroslaw KALISIAK, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Artur Karenovich MAILYAN, Debashis MANDAL, Guillaume MATA, Hyunyoung MOON, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Zhang WANG, Xuelei YAN, Kai YU
  • AXL COMPOUNDS
    Publication number: 20240246967
    Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by AXL.
    Type: Application
    Filed: May 20, 2022
    Publication date: July 25, 2024
    Inventors: Corinne Nicole FOLEY, Manjunath LAMANI, Manmohan Reddy LELETI, Dillon Harding MILES, Pradeep NAREDDY, Srinivas PALADUGU, Jay Patrick POWERS, Shiwei QU, Joice THOMAS, Ehesan Ul SHARIF, Rebecca Louise GRANGE, Guiling ZHAO
  • AXL INHIBITOR COMPOUNDS
    Publication number: 20240226115
    Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by AXL.
    Type: Application
    Filed: May 20, 2022
    Publication date: July 11, 2024
    Inventors: Corinne Nicole FOLEY, Manjunath LAMANI, Manmohan Reddy LELETI, Dillon Harding MILES, Srinivas PALADUGU, Jay Patrick POWERS, Shiwei QU, Ehesan Ul SHARIF, Rebecca Louise GRANGE, Guiling ZHAO
  • Solid forms of an azolopyrimidine compound
    Patent number: 11993584
    Abstract: The present invention provides solid forms, solvates and hydrates of 3-[2-amino-6-(1-{[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl}-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl]-2-methylbenzonitrile (Compound I), and methods of making and using the same.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: May 28, 2024
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Jenna Leigh Jeffrey, Manmohan Reddy Leleti, Dillon Harding Miles, Jay Patrick Powers